ELAVL1

Across TCGA pan-cancer cohorts, ELAVL1 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated ELAVL1 data layer compared with 26 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ELAVL1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ELAVL1 expression acts as an unfavorable survival marker.

HNSC, DLBC, and LIHC are the cancer types where ELAVL1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.203	0.713	<.001	45	view →
DLBC	DFS	Median	II,III,IV	0.065	0.829	<.001	18	view →
LIHC	OS	Median	All	0.031	0.775	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →
LUSC	DFS	Median	All	0.136	0.791	.005	3	view →
COAD	DFS	Median	II,III,IV	0.140	0.743	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

ELAVL1–HNSC (DFS)

Open the HNSC breakdown →